Acne vulgaris — affecting approximately 85% of adolescents and 30–50% of adults in developed countries — is the most common dermatological condition worldwide and the dermatology diagnosis with perhaps the widest gap between available evidence-based treatment and real-world care quality. Updated AAD (American Academy of Dermatology) guidelines in 2024 incorporated significant changes from earlier iterations: stronger emphasis on antibiotic stewardship, formal inclusion of clascoterone (Winlevi) — the first FDA-approved topical anti-androgen — updated isotretinoin dosing evidence, and recognition of novel light-based and biologics-adjacent therapies. The acne treatment algorithm in 2025 is more sophisticated, evidence-grounded, and antibiotic-conservative than at any previous point.
First-Line Topical Treatment: Retinoids + Benzoyl Peroxide
The evidence-based cornerstone of mild-to-moderate acne treatment is the combination of topical retinoid (normalizing follicular keratinization and preventing comedone formation) + benzoyl peroxide (BPO, potent bactericidal) — with or without topical antibiotic for inflammatory lesions. The 2024 AAD guidelines reinforce this combination as first-line, noting that topical antibiotics should not be used as monotherapy due to antibiotic resistance development. Adapalene 0.1% (Differin, now OTC) and BPO 2.5% (now available in Epiduo OTC formulation) provide excellent first-line management accessible without prescription. Fixed-dose combinations (Epiduo Forte 0.3% adapalene + 2.5% BPO, Tactupump Forte) achieve superior outcomes to monotherapy components and simplify regimen adherence — a practical advantage in a patient population with notoriously low adherence rates.
Antibiotic Stewardship
The concern about antibiotic resistance — particularly C. acnes resistance to erythromycin (resistance rates >50% in many countries) and tetracyclines (rising) — has driven the AAD's strong stewardship guidelines: (1) topical antibiotics (clindamycin, erythromycin) should always be combined with BPO to limit resistance; (2) oral antibiotics should be limited to ≤3 months of use before reassessment; (3) oral antibiotics should always be used in combination with a topical retinoid and BPO; (4) patients colonized with resistant strains should be switched to isotretinoin or clascoterone rather than antibiotic dose escalation. Sarecycline (Seysara) — a narrow-spectrum tetracycline approved for acne with reduced activity against gut flora compared to doxycycline — represents a stewardship-aligned antibiotic option for moderate-to-severe inflammatory acne.
Clascoterone: The First Topical Anti-Androgen
Clascoterone 1% cream (Winlevi, FDA-approved 2020 for both male and female acne) is the first topical androgen receptor blocker for acne — competing with DHT at androgen receptors in sebaceous glands to reduce sebum production directly. Phase 3 trials: significant reduction in inflammatory lesion counts at 12 weeks versus vehicle; safety profile superior to spironolactone (a systemic anti-androgen used off-label for female acne) due to topical administration minimizing systemic hormonal effects. Clascoterone is FDA-approved for use in males — an important distinction from systemic anti-androgens which are contraindicated in males due to feminizing effects. Clinical skincare and wound care products for dermatological practice can be sourced through our skin care catalog.
